Concepts and practices used to develop functional PLGA-based nanoparticulate systems

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 747-765

  Sah, Hongkee ^a,b   Thoma, Laura A ^b   Desu, Hari R ^b   Sah, Edel ^c   Wood, George C ^b  

^a Ewha Womans University   (South Korea)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Functionality; Nanoparticles; Nanoparticulate dosage forms; Polylactide co glycolide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CELL PENETRATING PEPTIDE; CLODRONIC ACID; DNA; DOXORUBICIN; FOLIC ACID; GADOLINIUM CHELATE; LACTIC ACID; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYETHYLENEIMINE; POLYGLACTIN; POLYMER; RAPAMYCIN; SIALIC ACID; TARIQUIDAR;

BINDING AFFINITY; BIODEGRADATION; BLOOD BRAIN BARRIER; BONE CANCER; BONE DISEASE; BREAST CANCER; DENDRITIC CELL; DNA TRANSFECTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; ENDOCYTOSIS; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HYDROGEN BOND; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOGENICITY; INTERNALIZATION; MICELLE; MOLECULAR WEIGHT; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSONIZATION; PARTICLE SIZE; PHOTOSENSITIZATION; PHYSICAL CHEMISTRY; POLYMERIZATION; REVIEW; SOLUBILIZATION; SPECIES TRANSLOCATION; STEREOCHEMISTRY; SURVIVAL RATE; ZETA POTENTIAL;

FUNCTIONALITY; NANOPARTICLES; NANOPARTICULATE DOSAGE FORMS; POLYLACTIDE-CO-GLYCOLIDE;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; LACTIC ACID; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84874357219     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S40579     Document Type: Review

References (168)

1. Panyama J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-347.
2. Danhier F, Ansorena E, Silva JM, Coco R, Breton AL, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release. 2012;161(2):505-522.
3. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95(8):4607-4612.
4. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-284.
5. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9): 771-782.
6. Peer D, Karp JM, Hong S, Farokhzard OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
7. Houchin ML, Topp EM. Chemical degradation of peptides and proteins in PLGA: A review of reactions and mechanisms. J Pharm Sci. 2008;97(7): 2395-2404.
8. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials. 2006;27(24):4356-4373.
9. Wonganan P, Croyle MA. PEGylated adenoviruses: from mice to monkeys. Viruses. 2010;2(2):468-502.
10. Yasugi K, Nagasaki Y, Kato M, Kataoka K. Preparation and characterization of polymer micelles from poly(ethylene glycol)-poly(d, l-lactide) block copolymers as potential drug carrier. J Control Release. 1999;62(1-2):89-100.
11. Beletsi A, Leontiadis L, Klepetsanis P, Ithakissios DS, Avgoustakis K. Effect of preparative variables on the properties of poly(dl-lactide-co-glycolide)-methoxypoly(ethyleneglycol) copolymers related to their application in controlled drug delivery. Int J Pharm. 1999;182(2):187-197.
12. Kissel T, Li Y, Unger F. ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins. Adv Drug Deliv Rev. 2002;54(1):99-134.
13. Kim SC, Kim DW, Shim YH, et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001;72(1-3):191-202.
14. Ghahremankhani AA, Dorkoosh F, Dinarvand R. PLGA-PEG-PLGA triblock copolymers as an in-situ gel forming system for calcitonin delivery. Polym Bull. 2007;59(5):637-646.
15. Li Y, Pei Y, Zhang X, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release. 2001;71(2):203-211.
16. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science. 2003;300(5619): 615-618.
17. Seo MH, Kim BO, Choi IJ, Shim JS, inventors; Samyang Corporation, assignee. Biodegradable branched polylactide derivatives capable of forming polymeric micelles, and their preparation method and use. United States patent US 8021652. September 20, 2011.
18. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10(11):3708-3716.
19. Shin HC, Cho H, Lai TC, Kozak KR, Kolesar JM, Kwon GS. Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. J Control Release. 2012; 163(1):93-99.
20. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007;24(6): 1029-1046.
21. Song Z, Feng R, Sun M, et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci. 2011;354(1):116-123.
22. Kwon GS, inventor; Wisconsin Alumni Research Foundation, assignee. Micelle encapsulation of therapeutic agents. United States patent application 20120276171. November 1, 2012.
23. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3(5):380-387.
24. Vrouenraets MB, Visser GW, Snow GB, van Dongen GA. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res. 2003;23(1B):505-522.
25. Ding H, Mora R, Gao J, Sumer BD. Characterization and optimization of mTHPP nanoparticles for photodynamic therapy of head and neck cancer. Otolaryngol Head Neck Surg. 2011;145(4):612-617.
26. Cohen EM, Ding H, Kessinger CW, Khemtong C, Gao J, Sumer BD. Polymeric micelle nanoparticles for photodynamic treatment of head and neck cancer cells. Otolaryngol Head Neck Surg. 2010;143(1):109-115.
27. Zhang H, Xia H, Wang J, Li Y. High intensity focused ultrasound-responsive release behavior of PLA-b-PEG copolymer micelles. J Control Release. 2009;139(1):31-39.
28. Trimaille T, Gurny R, Möller M. Synthesis and properties of novel poly(hexyl-substituted lactides) for pharmaceutical applications. Chimia. 2005;59(6):348-352.
29. Trimaille T, Gurny R, Möller M. Poly(hexyl-substituted lactides): novel injectable hydrophobic drug delivery systems. J Biomed Mater Res A. 2007;80(1):55-65.
30. Kasimova AO, Pavan GM, Danani A, et al. Validation of a novel molecular dynamics simulation approach for lipophilic drug incorporation into polymer micelles. J Phys Chem B. 2012;116(14):4338-4345.
31. Helander IM, Alakomi HL, Latva-Kala K, Koski P. Polyethyleneimine is an effective permeabilizer of Gram-negative bacteria. Microbiology. 1997;143(Pt 10):3193-3199.
32. Kirchelis R, Wightman L, Wagner E. Design and gene delivery activity of modified polyethyleneimines. Adv Drug Deliv Rev. 2001;53(3): 341-358.
33. Nam YS, Kang HS, Park JY, Park TG, Han SH, Chang IS. New micelle-like polymer aggregates made from PEI-PLGA diblock copolymers: micellar characteristics and cellular uptake. Biomaterials. 2003;24(12):2053-2059.
34. Sun J, Chen X, Lu T, et al. Formation of reversible shell cross-linked micelles from the biodegradable amphiphilic diblock copolymer poly(L-cysteine)-block-poly(L-lactide). Langmuir. 2008;24(18): 10099-10106.
35. Arimura H, Ohya Y, Ouchi T. Formation of core-shell type biodegradable polymeric micelles from amphiphilic poly(aspartic acid)-block-polylactide diblock copolymer. Biomaterials. 2005;6(2):720-725.
36. Sun J, Deng C, Chen X, et al. Self-assembly of polypeptide-containing ABC-type triblock copolymers in aqueous solution and its pH dependence. Biomacromolecules. 2007;8(3):1013-1017.
37. Jeong JH, Byun Y, Park TG. Synthesis and characterization of poly(L-lysine)-g-poly(D, L-lactic-co-glycolic acid) biodegradable micelles. J Biomater Sci Polym Ed. 2003;14(1):1-11.
38. Lee SH, Mok H, Lee Y, Park TG. Self-assembled siRNA-PLGA conjugate micelles for gene silencing. J Control Release. 2011;152(1): 152-158.
39. Kim TI, Lee M, Kim SW. A guanidinylated bioreducible polymer with high nuclear localization ability for gene delivery systems. Biomaterials. 2010;31(7):1798-1804.
40. Jeong JH, Park TG. Novel polymer-DNA hybrid polymeric micelles composed of hydrophobic poly(d, l-lactic-co-glycolic acid) and hydrophilic oligonucleotides. Bioconjug Chem. 2001;12(8):917-923.
41. Mishra D, Kang HC, Bae YH. Reconstitutable charged polymeric (PLGA)2-b-PEI micelles for gene therapeutics delivery. Biomaterials. 2011;32(15):3845-3854.
42. Fu C, Sun X, Liu D, Chen Z, Lu Z, Zhang N. Biodegradable tri-block copolymer poly(lactic acid)-poly(ethylene glycol)-poly(l-lysine) (PLA-PEG-PLL) as non-viral vector to enhance gene transfection. Int J Mol Sci. 2011;12(2):1371-1388.
43. Bae Y, Fukushima S, Harada A, Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew Chem Int Ed Engl. 2003;42(38):4640-4643.
44. Wang CH, Wang CH, Hsiue GH. Polymeric micelles with a pH-responsive structure as intracellular drug carriers. J Control Release. 2005;108(1):140-149.
45. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2(1):8-21.
46. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating poly(ethylene glycol)-poly(lactide) block copolymer micelles with modulated surface charge. J Control Release. 2001;77(1-2):27-38.
47. Sheng Y, Yuan Y, Liu C, Tao X, Shan X, Xu F. In vitro macrophage uptake and in vivo biodistribution of PLA-PEG naoparticles loaded with hemoglobin as blood substitutes: effect of PEG content. J Mater Sci Mater Med. 2009;20(9):1881-1891.
48. Beletsi A, Panagi Z, Avgoustakis K. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int J Pharm. 2005;298(1):233-241.
49. Verrecchia T, Spenlehauer G, Bazile DV, Murry-Brelier A, Archimbaud Y, Veillard M. Non-stealth (poly(lactic acid/albumin) and stealth (poly(lactic acid-polyethylene glycol) nanoparticles as injectable carriers. J Control Release. 1995;36(1-2):49-61.
50. Suh J, Choy KL, Lai SK, et al. PEGylation of nanoparticles improves their cytoplasmic transport. Int J Nanomedicine. 2007;2(4): 735-741.
51. Pamujulas S, Hazari S, Bolden G, et al. Cellular delivery of PEGylated PLGA nanoparticles. J Pharm Pharmacol. 2012;64(1): 61-67.
52. Li M, Panagi Z, Avgoustakis K, Reineke J. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content. Int J Nanomedicine. 2012;7:1345-1356.
53. Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4(2):219-233.
54. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49(36):6288-6308.
55. Gref R, Babak B, Bouillot P, Lukina I, Bodorev M, Dellacherie E. Interfacial and emulsion stabilizing properties of amphiphilic water-soluble poly(ethylene glycol)-poly(lactic acid) copolymers for the fabrication of biocompatible nanoparticles. Colloids Surf A Physicochem Eng Asp. 1998;143(2-3):413-420.
56. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463-478.
57. Feczkó T, Tóth J, Dósa Gy, Gyenis J. Influence of process conditions on the mean size of PLGA nanoparticles. Chem Eng Process. 2011;50(8): 846-853.
58. Javadzadeh Y, Ahadi F, Davaran S, Mohammadi G, Sabzevari A, Adibkia K. Preparation and physicochemical characterization of naproxen-PLGA nanoparticles. Colloids Surf B Biointerfaces. 2010;81(2):498-502.
59. Sanguansri P, Augustin MA, Nanoscale materials development-a food industry perspective. Trends Food Sci Tech. 2006;17(10):547-556.
60. Schubert H, Ax K, Behrend O. Product engineering of dispersed systems. Trends Food Sci Tech. 2003;14(1-2):9-16.
61. Discher DE, Ortiz V, Srinivas G, et al. Emerging application of polymersomes in delivery: From molecular dynamics to shrinkage of tumors. Polym Sci. 2007;32(8-9):838-857.
62. Discher BM, Won YT, Ege DS, et al. Polymersomes: tough vesicles made from diblock copolymers. Science. 1999;284(5417):1143-1146.
63. Discher DE, Eisenberg A. Polymer vesicles. Science. 2002;297(5583): 967-973.
64. Meng F, Hiemstra C, Engbers GHM, Feijen J. Biodegradable polymersomes. Macromolecules. 2003;36(9):3004-3006.
65. Shimada K, Matsuo S, Sadzuka Y, et al. Determination of incorporated amounts of poly(ethylene glycol)-derivatized lipids in liposomes for the physicochemical characterization of stealth liposomes. Int J Pharm. 2000;203(1-2):255-263.
66. Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlation with PEG molecular weight. J Control Release. 2003;90(3):323-334.
67. Ahmed F, Pakunlu RI, Brannan A, Bates FS, Minko T, Discher DE. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. J Control Release. 2006;116(2):150-158.
68. Ahmed F, Pakunlu RI, Srinivas G, et al. Shrinkage of a rapidly growing tumor by drug-loaded polymersomes: pH-triggered release through copolymer degradation. Mol Pharm. 2006;3(3):340-350.
69. Rangel-Yagui CO, Pessoa A Jr, Tavares LC. Micellar solubilization of drugs. J Pharm Pharm Sci. 2005;8(2):147-163.
70. Ahmed F, Discher DE. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. J Control Release. 2004;96(1):37-53.
71. Chan JM, Zhang LE, Yuet KP, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009;30(8): 1627-1634.
72. Zhang L, Zhang L. Lipid-polymer hybrid nanoparticles: synthesis, characterization and applications. Nano Life. 2010;1(1-2):163-173.
73. Thevenot J, Troutier AL, David L, Delair T, Ladaviere C. Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. Biomacromolecules. 2007;8(11):3651-3660.
74. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
75. Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8): 1696-1702.
76. De Miguel I, Imbertie L, Rieumajou V, Major M, Kravtzoff R, Betbeder D. Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers. Pharm Res. 2000;17(7):817-824.
77. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005;436(7050):568-572.
78. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (Lond). 2007;2(2):219-232.
79. Wang Y, Wang R, Lu X, Lu W, Zhang C, Liang W. Pegylated phospholipids-based self-assembly with water-soluble drugs. Pharm Res. 2010;27(2):361-370.
80. Li Y, Taulier N, Rauth AM, Wu XY. Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN). Pharm Res. 2006;23(8):1877-1887.
81. Ling G, Zhang P, Zhang W, et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release. 2010;148(2): 241-248.
82. Kreuter J, Gelperina S, Maksimenko O, Khalanskiy A, inventors; LTS Lohmann Therapie-Systeme-AG, assignee. Polylatide nanoparticles. United States patent US 8003128. August 23, 2011.
83. Mu L, Seow PH. Application of TPGS link polymeric nanoparticulate drug delivery system. Colloids Surf B Biointerfaces. 2006;47(1):90-97.
84. Nafee N, Schneider M, Schaefera UF, Lehra CM. Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. Int J Pharm. 2009;381(2):130-139.
85. Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaumont E, Fernandes JC. Chitosan-DNA nanoparticles as non-viral vectors in gene delivery: strategies to improve transfection efficacy. Eur J Pharm Biopharm. 2004;57(1):1-8.
86. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007;3(3):173-183.
87. Ravi Kumar MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25(10):1771-1777.
88. Zhao P, Wang H, Yu M, et al. Paclitaxel loaded folic acid targeted nanoparticles of mixed lipid-shell and polymer-core: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2012;81(2):248-256.
89. Hu CMJ, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A. 2011;108(27):10980-10985.
90. Weiss B, Schneider M, Muys L, et al. Coupling of biotin-(poly(ethylene glycol)amine to poly(D, L-lactide-co-glycolide) nanoparticles for versatile surface modification. Bioconjug Chem. 2007;18(4):1087-1094.
91. Pignatello R, Sarpietro MG, Castelli F. Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties. J Funct Biomater. 2012;3(1):79-99.
92. Pignatello R, Cenni E, Micieli D, et al. A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate. Nanomedicine (Lond). 2009;4(2):161-175.
93. Frith JC, Mönkkönen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1997;12(9):1358-1367.
94. Shmeeda H, Gabizon AA, inventors; Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd, assignee. Targeted liposomes comprising n-containing bisphosphonates and uses of thereof. United States patent application 20120100206. April 26, 2012.
95. Hafeman S, London C, Elmslie R, Dow S. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol Immunother. 2010;59(3):441-452.
96. Guth AM, Hafeman SD, Dow SW. Depletion of phagocytic myeloid cells triggers spontaneous T cell-and NK cell-dependent antitumor activity. OncoImmunology. 2012;1(8):1248-1257.
97. Smith J, Sharma G, inventors. Targeting tumor associated macrophages using bisphosphonate-loaded particles. United States patent application 20110311616. December 22, 2011.
98. Song Q, Yao L, Huang M, et al. Mechanism of transcelluar transport of wheat germ agglutinin-functionalized polymeric nanoparticles in Caco-2-cells. Biomaterials. 2012;33(28):6769-6782.
99. Wang C, Ho PC, Lim LY. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int J Pharm. 2010;400(1-2):201-210.
100. Mo Y, Lim LY. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. J Pharm Sci. 2004;93(1):20-28.
101. Wen Z, Yan Z, Hu K, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release. 2011;151(2):131-138.
102. Gao X, Tao W, Lu W, et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intransal administration. Biomaterials. 2006;27(18):3482-3490.
103. van Kooyk Y. C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem Soc Trans. 2008;36(Pt 6):1478-1481.
104. Ghotbi Z, Haddadi A, Hamdy S, Hung RW, Samuel J, Lavasanifar A. Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. J Drug Target. 2011;19(4):281-292.
105. Tosi G, Vergoni AV, Ruozi B, et al. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution. J Control Release. 2010;145(1):49-57.
106. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier. J Control Release. 2005;108(1):84-96.
107. Michaelis K, Hoffmann MM, Dreis S, et al. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhance drug transport to the brain. J Pharm Exp Ther. 2006;317(3):1246-1253.
108. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res. 1997;14(3):325-328.
109. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release. 2009;136(1):21-29.
110. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2010;31(2):358-365.
111. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues. Cancer. 1994; 73(9):2432-2443.
112. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 2004;96(2):273-283.
113. Wang S, Luo Y, Zeng S, et al. Dodeanol-poly(D, L-lactic acid)-b-poly(ethylene glycol)-folate (Dol-PLA-PEG-FA) nanoparticles: evaluation of cell cytotoxicity and selecting capability in vitro. Colloids Surf B Biointerfaces. 2013;102(1):130-135.
114. Wang CH, Hsiue GH. Polymer-DNA hybrid nanoparticles based on folate-polyethyleneimine-block-poly(L-lactide). Bioconjug Chem. 2005;16(2):391-396.
115. Esmaeili F, Ghahremani MH, Ostad SB, et al. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target. 2008;16(5):415-423.
116. Sunoqrot S, Bae JW, Pearson RM, et al. Temporal control over cellular targeting through hybridization of folate-targeted dendrimers and PEG-PLA nanoparticles. Biomacromolecules. 2012;13(4): 1223-1230.
117. Högemann-Savellano D, Bos E, Blondet C, et al. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia. 2003;5(6):495-506.
118. Shah N, Chaudhari K, Dantuluri P, Murthy RS, Das S. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic 85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target. 2009;17(7): 533-542.
119. Chang J, Paillard A, Passirani C, et al. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res. 2012;29(8): 1495-1505.
120. Zheng Y, Yu B, Weecharangsan W, et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7α-APTADD to breast cancer cells. Int J Pharm. 2010;390(2): 234-241.
121. Eavarone DA, Yu X, Bellamkonda RV. Targeted drug delivery to C6glioma by tranferrin-coupled liposomes. J Biomed Mater Res. 2000;51(1):10-14.
122. Yang X, Koh CG, Liu S, et al. Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm. 2009;6(1):221-230.
123. Hersel U, Dahmen C, Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials. 2003; 24(24):4385-4415.
124. Ding H, Yong KT, Roy I, et al. Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers. Nanotechnology. 2011;22(16):165101.
125. Toti US, Guru BR, Grill AE, Panyam J. Interfacial activity assisted surface functionalization: a novel approach to incorporate maleimide functional groups and cRGD peptide on polymeric nanoparticles for targeted drug delivery. Mol Pharm. 2010;7(4):1108-1117.
126. Hrkach JS, Ou J, Lotan N, Langer R. Synthesis of poly(L-lactic acid-co-L-lysine) graft copolymers. Macromolecules. 1995;28(13): 4736-4739.
127. Quirk RA, Chan WC, Davies MC, Tendler SJ, Shakesheff KM. Poly(L-lysine)-GRGDS as a biomimetic surface modifier for poly(lactic acid). Biomaterials. 2001;22(8):865-872.
128. Herbig ME, Weller KM, Merkle HP. Reviewing biophysical and cell biological methodologies in cell-penetrating peptide (CPP) research. Crit Rev Ther Drug Carrier Syst. 2007;24(3):203-255.
129. Chugh A, Eudes F, Shim YS. Cell-penetrating peptides: nanocarrier for macromolecule delivery in living cells. IUBMB Life. 2010;62(3): 183-193.
130. Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials. 2010;31(8):2278-2292.
131. Xia H, Gao X, Gu G, et al. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharm. 2012;436(1-2): 840-850.
132. Nam YS, Park JY, Han SH, Chang IS. Intracellular drug delivery using poly(D, L-lactide-co-glycolide) nanoparticles derivatized with a peptide from a transcriptional activator protein of HIV-1. Biotechnol Lett. 2002;24(24):2093-2098.
133. Chen J, Li S, Shen Q. Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery. Eur J Pharm Sci. 2012;47(2):430-443.
134. Sethuraman VA, Lee MC, Bae YH. A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm Res. 2008;25(3):657-667.
135. Khondee S, Baoum A, Siahaan TJ, Berkland C. Calcium condensed LABL-TAT complexes effectively target gene delivery to ICAM-1 expressing cells. Mol Pharm. 2011;8(3):788-798.
136. Chittasupho C, Xie SX, Baoum A, Yakovleva T, Siahaan TJ, Berkland CJ. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci. 2009;37(2):141-150.
137. Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C. PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug Chem. 2008;19(1):145-152.
138. Cirstoiu-Hapca A, Bossy-Nobs L, Buchegger F, Gurny R, Delie F. Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticles. Int J Pharm. 2007;331(2):190-196.
139. Koopaei MN, Dinarvand R, Amini M, et al. Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int J Nanomedicine. 2011;6:1903-1912.
140. Mitra M, Misra R, Harilal A, Sahoo SK, Krishnakumar S. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol Vis. 2011;17:2724-2737.
141. Muro S, Cui X, Gajewski C, Murciano JC, Myzykantov VR, Koval M. Slow intracellular trafficking of catalse nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physiol Cell Physiol. 2003;285(5):C1339-C1347.
142. Fay F, McLaughlin KM, Small DM, et al. Conatumumab (AMG 655) coated nanoparticles for targeted pro-apototic drug delivery. Biomaterials. 2011;32(33):8645-8653.
143. Obemajer N, Kocbek P, Repnik U, et al. Immunonanoparticles-an effective tool to impair harmful proteolysis in invasive breast tumor cells. FEBS J. 2007;274(17):4416-4427.
144. McLoman DP, Barret T, Cummins R, et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res. 2010;16(13):3442-3451.
145. McCarron PA, Marouf WM, Quinn DJ, et al. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem. 2008;19(8):1561-1569.
146. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release. 2007;120(1-2):18-26.
147. Nobs L, Buchegger F, Gurny R, Allémann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci. 2004;93(8):1980-1992.
148. Shi N, Zhang Y, Zhu C, Boado RJ, Pardrige WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S A. 2001;98(22):12754-12759.
149. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm Res. 2002;19(8):137-143.
150. Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease. Nanomedicine. 2012;8(2):250-260.
151. Kempf M, Mandal B, Jilek S, et al. Improved simulation of human dendritic cells by receptor engagement with surface-modified microparticles. J Drug Target. 2003;11(1):11-18.
152. Wei H, Wang S, Zhang D, et al. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res. 2009;15(14):4612-4621.
153. Barbas AS, Mi J, Clary BM, White RR. Aptamer applications for targeted cancer therapy. Future Oncol. 2010;6(7):1117-1126.
154. Ng E, Shima D, Calias P, Cunningham E Jr, Guyer D, Adamis A. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5(2):123-132.
155. Hovanessian AG, Soundaramourty C, El KD, Nondier I, Svab J, Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium dependent ligand internalization. PLoS One. 2010;5(12):e15787.
156. Hwang DW, Ko HY, Lee JH, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med. 2010;51(1):98-105.
157. Reyes-Reyes EM, Teng Y, Bates PL. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 2010;70(21):8617-8629.
158. Guo J, Gao X, Su L, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32(31):10-20.
159. Aravind A, Jeyamothan P, Nair R, et al. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng. 2012;109(11):2920-2931.
160. Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol. 2010;624:163-175.
161. Gu F, Langer R, Farokhzad OC. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol. 2009;544:589-598.
162. Farokhzad OC, Jon S, Khademhosseini A, Tran TNT, LaVan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004;64(21):7668-7672.
163. Wang L, Neoh K, Kang E, Shuter B, Wang S. Biodegradable magnetic-fluorescent magnetite/poly(dl-lactic acid-co-α, β-malic acid) composite nanoparticles for stem cell labeling. Biomaterials. 2010;31(13):3502-3511.
164. Lim YT, Noh Y, Han JH, Cai Q, Yoon K, Chung BH. Biocompatible polymer-nanoparticle-based bimodal imaging contrast agents for the labeling and tracking of dendritic cells. Small. 2008;4(10): 1640-1645.
165. Chen Z, Yu D, Liu C, et al. Gadolinium-conjugated PLA-PEG nanoparticles as liver targeted molecular MRI contrast agent. J Drug Target. 2011;19(8):657-665.
166. Doiron AL, Homan KA, Emelianov S, Brannon-Peppas L. Poly(lactic-co-glycolic) acid as a carrier for imaging contrast agents. Pharm Res. 2009;26(3):674-682.
167. Lee SJ, Jeong JR, Shin SC, et al. Intracellular translocation of superparamagnetic iron oxide nanoparticles encapsulated with peptide-conjugated poly (D, L lactide-co-glycolide). J Appl Phys. 2005;97(10):Q913-1-Q913-3.
168. Yang J, Lee CH, Park J, et al. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem. 2007;17:2695-2699.